DXS International PLC - Leicestershire, England-based healthcare information and clinical decision support systems - Posts revenue of GB1.7 million for the six months that ended on October 31, up 6.3% from GBP1.6 million a year earlier. However, swings to a pretax loss of GBP131,269 from a profit of GBP21,427 due to "increased operating costs and depreciation", it explains. Cost of sales increases to GBP229,308 from GBP181,952 a year before. Depreciation & amortisation rises to GBP354,363 from GBP274,093.

Chief Executive Officer David Immelman says: "With the persistent challenges facing the [UK National Health Service], our solutions have never been more aligned to NHS priorities. Our new products are currently being trialled in numerous clinical commissioning groups with significant results demonstrated in reducing referral rejections and drastically cutting waiting times. We are solely focused in converting these trials to commercial contracts."

Current stock price: last traded on Nov 30 at 4.5 pence each

12-month change: down from 14p on Jan 20 last year

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.